Different released rapamycin eluting stents to reduce in-stent neointimal hyperplasia in a porcine coronary model

徐卫亭,洪小苏,陈建昌,霍勇,陈明,洪涛,高炜
DOI: https://doi.org/10.3969/j.issn.0253-3685.2004.10.002
2004-01-01
Abstract:Objective Neointimal proliferation has played an important role in in-stent restenosis.Recent studies demonstrated that drug-eluting stents could prevent in-stent restenosis by inhibiting neointimal proliferation.The purpose of this study was to determine the efficacy of two different released rapamycin eluting stents to reduce in-stent neointimal hyperplasia.Methods Stents were coated with PLGA(poly/lactic-co-Gly-Colicacid)polymer containing 65~90 μg rapamycin(slow release)or 68~96 μg rapamycin(fast release)respectively.Twenty stents(metal group,n=8;slow released group,n=5;fast released group,n=7)were implanted in the coronary arteries of 20 pigs.Results After 28 days,the mean neointimal was 2.18±1.03 mm 2 for the metal group.Compared with metal group the mean neointimal was significantly decresed in the slow released group(1.09±0.82 mm 2,P=0.0450)and the fast released grpup(0.94±0.88 mm 2,P=0.0156).There is no difference between two Rapamycin groups(P=0.7692).The in-stent restenosis was 25% in metal group and 0% in two rapamycin groups 28 days later.Conclusion Stent-based delivery of Rapamycin is feasible and effectively reduces in-stent neointimal hyperplasia by inhibiting cellular proliferation and can be safely used.
What problem does this paper attempt to address?